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Introduction
　Gemtuzumab ozogamicin （GO） is a new chemotherapy agent targeting CD33-positive 
acute myeloid leukemia （AML）.  GO is composed of recombinant humanized IgG4 anti-
CD33 mouse monoclonal antibody conjugated with the antitumor antibiotic, calicheamicin-γ11）. 
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Abstract : It is difcult to predict the clinical outcome of gemtuzumab ozo-
gamicin （GO） therapy based solely on the previously identified predictive 
factors.  We retrospectively analyzed the relationship between clinical factors 
and outcomes in 12 patients with relapsed or refractory acute leukemia who 
received GO monotherapy.  The median patient age at initial GO infusion was 
56 years, and the average initial dosage was 8.1 mg/m2.  Four patients （33%） 
achieved an overall remission （OR）.  The time from diagnosis to GO infusion 
was signicantly longer in patients with OR than in patients with no remission 
（NR）（1747 vs. 501 days, respectively ; P＜ 0.01）.  The number of karyotype 
abnormalities before GO infusion was signicantly greater in NR patients （9.5） 
than in OR patients （0.5 ; P＝ 0.03）.  Monocyte counts in the bone marrow 
before GO therapy were signicantly lower in OR than in NR patients （100/
µL vs. 1080/μL, respectively ; P＝ 0.048）.  In a multivariate analysis, monocyte 
count was signicantly associated with overall survival （P ＝ 0.005）.  CD14 
expression in OR patients was lower than in NR patients, with the exception 
of 4 patients whose French-American-British subtypes were M4 or M5 （OR, 
0.3% ; NR, 2.5% ; P＝ 0.04）.  NR was noted in all 6 patients who underwent 
allogeneic stem cell transplantation before and/or after GO infusion.  Patients 
showing good sensitivity to conventional chemotherapy with good survival 
after diagnosis tend to be sensitive to GO as well.  A low monocyte count in 
the bone marrow at infusion of GO might indicate improved efcacy of GO 
therapy.  Further investigation is warranted for establishing appropriate patient 
selection and for clarifying efcient conditions for GO therapy.
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In Japan, GO has been approved as a monotherapy treatment for relapsed or refractory 
CD33-positive AML since 2005.  However, GO monotherapy has had limited efficacy 2）. 
Similar to non-Japanese studies, the overall remission （OR） rate for GO monotherapy has 
been reported as 30% in a Japanese phase II study 2, 3）.  The following predictive factors 
affecting the clinical outcome of GO therapy have been identified in previous studies : 
P-glycoprotein activity and expression1, 4）, multi-drug resistance protein （ATP-binding cas-
sette, sub-family C, member）4）, white blood cell （WBC） count at the start of GO therapy 5）, 
CD33-antigen loads in peripheral blood （PB）6）, duration of initial complete remission 7）, and 
cytogenetic risk 7）.  However, it is difcult to predict the outcome of GO therapy based on 
these factors alone.  Additionally, there have been no reports regarding predictive factors 
that affect clinical outcomes of GO therapy among Japanese patients.  In our study, we 
retrospectively evaluated the use of GO in 12 patients treated at our hospital and analyzed 
the pretreatment factors that affected their clinical outcome.
Patients and Methods
Patients
　Twelve patients with relapsed/refractory de novo acute leukemia who were treated with 
GO at our hospital between September 2007 and August 2009 were included in this study. 
Informed consent was obtained from each patient before initiation of GO therapy.  Patient 
follow-ups were updated on December 31, 2009.  The subtypes of leukemia were classied 
as M1 （n＝ 2）, M2 （n＝ 5）, M4 （n＝ 2）, and M5 （n＝ 2）, based on the French-American-
British （FAB） classification ; the remaining patient was classified as a mixed phenotype 
acute leukemia, B/myeloid, not otherwise specied （n＝ 1）, based on the WHO classication 
of tumors of hematopoietic and lymphoid tissues （WHO classication, fourth edition, 2008）8）.
　Cytogenetic analyses were performed on bone marrow （BM） samples of all patients 
using the G-banding method at the time of diagnosis of leukemia and before GO infusion. 
Cytogenetic risk was categorized according to the Southwest Oncology Group （SWOG）9） 
and Medical Research Council （MRC）10） classification for cytogenetic risk.  Cell surface 
expression of CD33 and CD14 on the leukemic blasts in the pretreatment BM samples was 
determined by ow cytometry in all patients.
Efcacy measures
　Efcacy measures were categorized into the following 3 groups : complete remission （CR）, 
CR with incomplete platelet recovery （CRp）, and no remission （NR）7）.  CR was dened as : 
（I） the absence of leukemic blasts in PB ; （II） no more than 5% leukemic blasts in the BM, 
as measured by BM aspiration or biopsy samples ; （III） PB counts with hemoglobin con-
centration ≥ 9 g/dL, absolute neutrophil count ≥ 1500/μL, and platelet count ≥ 100,000/μL ; and 
（IV） red blood cell transfusion independence ≥ 2 weeks with platelet transfusion independence 
≥ 1 week.  CRp was similarly dened, but CRp platelet counts were <100,000/μL.  Patients 
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who did not satisfy the criteria for either CR or CRp were categorized as NR.  OR included 
both CR and CRp.  Determination of remission status was evaluated from 15 days to 70 days 
after the rst administration of GO.
　Overall survival （OS） was dened as the time from the rst GO infusion until death. 
Event-free survival was defined as the time from the first GO infusion until death or 
relapse of leukemia.  Duration of initial complete remission （CR1） of leukemia was dened 
as the time from diagnosis of CR1 to the rst relapse of leukemia.
Pretreatment factors
　Patients were divided into 2 groups based on the GO efcacy measures, i.e., the OR and 
NR groups.  In a univariate analysis, various factors （mentioned below） were compared 
between the 2 groups at the time of diagnosis of leukemia, before the rst GO infusion, 
and at the rst GO infusion.  The following factors were assessed at the time of diagnosis 
of leukemia : WBC count, percentage of leukemic blasts in PB, lactate dehydrogenase, 
nucleated cell count in BM, percentage of leukemic cells in BM, percentage of peroxidase-
positive leukemic blasts, the Eastern Cooperative Oncology Group （ECOG） performance 
status, number of karyotype abnormalities, and cytogenetic risk according to the SWOG and 
MRC classication systems.  The factors assessed before the rst GO infusion included the 
following : percentage of leukemic blasts in BM, leukemic blast count in BM, percentage of 
monocytes in BM, monocyte count in BM calculated as nucleated cell count in BM multi-
plied by the percentage of monocytes in BM divided by 100, percentage of leukemic cells 
in BM expressing CD14, percentage of leukemic cells in BM expressing CD33, number of 
karyotype abnormalities, and cytogenetic risk according to the SWOG and MRC classica-
tion systems.  The factors assessed at the rst GO infusion included patient age, frequency 
of relapse, ECOG performance status, duration of CR1, time since diagnosis of leukemia, 
number of chemotherapy regimens administered, WBC count, percentage of leukemic blasts 
in PB, leukemic blast count in PB, percentage of monocytes in PB, and monocyte count in 
PB.  Multivariate analysis was performed for OS and included signicant factors identied in 
the univariate analysis.
Safety measures
　Adverse events were graded using the Common Terminology Criteria for Adverse Events, 
version 3.0.  WBC counts from day 1 to day 14 after the rst GO infusion were compared 
between the 2 groups using the Wilcoxon test.  Unmeasured values of WBC counts were 
substituted by interpolated values derived from the adjacent values using linear interpolation.
Statistical analyses
　Survival curves were calculated according to the Kaplan-Meier method and compared 
using the log-rank test.  Univariate analysis was performed using the Wilcoxon test and chi-
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square analysis, while multivariate analysis was performed using the Cox regression analysis. 
Statistical analyses were performed using the software program, KyPlot, version 5.0 （Kyen-
sLab Co. Ltd., Tokyo, Japan）.  In all tests, P＜ 0.05 was considered signicant.
Results
Patient characteristics
　We evaluated 12 patients in this study.  The median age was 56 years （range, 27-85 years）, 
the male : female ratio was 6：6, and the mean observation time was 200 days （range, 16-642 
days）.  The patients’ leukemic status and laboratory data are presented in Tables 1 and 2. 
Patient characteristics are listed according to the categories of GO efcacy in Table 3.
Feasibility and treatment outcomes
　All 12 patients received the first dose of GO as a monotherapy, following which 8 
patients received 1 course and 1 patient received 3 courses of GO （1 course was dened as 
2 doses of GO）.  For the patients who received 2 or more doses, there was a median gap 
of 14 days （range, 9-54 days） between the rst and second doses.  The median initial dose 
was 8.1 mg/m2 （range, 5.8-9.1 mg/m2）.  CR, CRp, OR, and NR were observed in 2 （17%）, 
2 （17%）, 4 （33%）, and 8 patients （68%）, respectively （Table 1）.
Pretreatment factors according to efcacy measures
　The pretreatment factors listed above were compared between the OR and NR groups 
（Table 4）.  No clinical factors at the time of diagnosis of leukemia were signicantly associ-
ated with the clinical outcome, however a number of signicant differences between the 2 
groups were observed for factors before or at GO infusion.  The duration of CR1 and the 
duration between diagnosis of leukemia and the rst GO infusion were signicantly longer 
in OR patients.  The ECOG performance status was significantly greater in NR patients 
compared to OR patients （P＝ 0.03）.  In addition, the number of karyotype abnormalities 
before GO infusion was signicantly greater in NR patients than in OR patients （9.5 vs. 
0.5, respectively ; P＝ 0.03）, and the cytogenetic risk was also signicantly different between 
OR and NR patients, according to both the SWOG （P＝ 0.01） and MRC （P＝ 0.049） clas-
sication systems.  The percentage of leukemic blasts in the BM showing CD33 expression 
was not signicantly different between groups （P＝ 0.46）, but CD14 expression （a monocyte 
marker） on leukemic blasts in the BM was signicantly lower in OR patients than in NR 
patients （0.35% vs. 2.60%, respectively ; P ＝ 0.004）.  The monocyte count in the BM was 
also signicantly lower in OR patients than in NR patients （100/μL vs. 1084/μL, respectively ; 
P＝ 0.048）.  In the comparison of 8 patients with the exception of the 4 patients designated 
as FAB M4 （acute myelomonocytic leukemia） or M5 （acute monocytic leukemia）, CD14 
expression in 3 OR patients was consistently lower than in 5 NR patients （0.3% vs. 2.5%, 
respectively ; P＝ 0.04）.  The monocyte count in the PB of OR patients at the initial infu-
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sion of GO tended to be lower than in NR patients （OR, 14.0/μL ; NR, 790/μL ; P＝ 0.15）. 
In a multivariate analysis, the following factors were signicantly associated with OS : ECOG 
performance status （P＝ 0.001）, duration of CR1 （P＝ 0.007）, time between diagnosis of 
leukemia and rst GO infusion （P＝ 0.01）, monocyte count in the BM （P＝ 0.005）, and 
the number of karyotype abnormalities before GO infusion （P＝ 0.002）.
Survival according to efcacy measures
　The median OS was 77 days （391.5 days and 55.5 days for patients with OR and NR, 
respectively）.  The OS was signicantly longer in patients with OR than those with NR （P＝
0.03 ; Figs. 1 and 2）.  All the OR patients experienced relapses and the median event-free 
survival of OR patients was 140 days （range, 79-176 days ; Fig. 3）.  The causes of death 
were leukemia, sepsis, and multiple organ failure.
Table 3.  Characteristics of the patients accoding to the gemtuzumab ozogamicin efcacy measures
OR（4）
CR（2） CRp（2） NR（8） Total（12）
Sex
   Male 0 1 5 6
   Female 2 1 3 6
Age, median（range） 71.5（64-85） 46（27-85） 56（27-85）
State at 1st GO infusion
   Induction failure 0 0 1 1
   1st relapse 1 0 2 3
   2nd relapse 1 0 5 6
   3rd relapse 0 2 0 2
Subtype of leukemia
   AML M1（FAB） 0 1 1 2
   AML M2（FAB） 0 1 4 5
   AML M4（FAB） 0 0 2 2
   AML M5a（FAB） 0 0 1 1
   AML M5b（FAB） 1 0 0 1
   Mixed phenotype（WHO2008） 1 0 0 1
GO infusion after SCT＊ 0 0 5 5
   uBMT 0 0 2 2
   CBT 0 0 3 3
   Days from SCT to 1st GO , median（range） none in OR 107（42-231）
GO infusion before SCT＊ 0 0 2 2
   CBT 0 0 1 1
   rBMT 0 0 1 1
   Days from 1st GO to SCT, median（range） none in OR 20.5（18-23）
GO, gemtuzumab ozogamicin ; OR, overall response ; CR, complete remission ; CRp, CR with 
incomplete platelet recovery ; NR, no remission ; AML, acute myeloid leukemia ; FAB, French-
American-British classification ; SWOG, Southwest Oncology Group ; MRC, Medical Research 
Council ; SCT, stem cell transplantation ; uBMT, unrelated bone marrow transplantation ; CBT, cord 
blood transplantation ; rBMT, related bone marrow transplantation ; ＊, One patient in whom AML 
relapsed after uBMT and who received GO as pretherapy prior to CBT is duplicated.
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Outcome in patients who received allogeneic stem cell transplantation
　Overall, 6 patients received allogeneic stem cell transplantation （allo-SCT） - 5 before 
GO therapy and 2 after GO therapy ; 1 patient, whose AML relapsed after unrelated BM 
transplantation and who had received GO as pretherapy prior to cord blood transplantation, 
underwent allo-SCT both before and after GO therapy.  All patients who underwent allo-
SCT before or after GO treatment showed NR and died within 91 days of the initial GO 
infusion.  Veno-occlusive disease （VOD） was not observed in any of these patients.
Table 4. Pretreatment factors according to the gemtuzumab ozogamicin efcacy measures; mean（range）
　 OR NR
P value
in Univariate
analysis
P value
in Multivariate
analysis
Status at the time of diagnosis of leukemia
　WBC counts（× 103/μL） 32.9（2.19-67.0） 110（1.50-381） 0.57
　NCC in BM（× 104/μL） 21.2（1.4-38） 46.3（7-108） 0.28
Status at 1st GO infusion
　Age 73.0（64-85） 51.6（27-85） 0.11
　Times of relapse 2.3（1-3） 1.7（1-2） 0.31
　ECOG Performance status 1.3（1-2） 2.8（1-4） 0.03＊ 0.001＊
　Duration of CR1 （day） 1093.0（397-1474） 296.7（96-525） 0.01＊ 0.007＊
　Day from diagnosis of disease 1747.5（1113-2232） 501（201-803） 0.004＊ 0.01＊
　No. of treated chemotherapy regimens 2.75（2-4） 4.63（2-8） 0.15
Status of PB at 1st GO infusion
WBC counts（× 103/μL） 6.33（2.80-9.50） 11.1（0.500-24.0） 0.68
Leukemic blasts（%） 51.5（1.0-78.0） 46.8（1.0-99.0） 0.93
Leukemic blast counts（×103/μL） 3.99（0.028-7.41） 7.11（0.044-17.0） 0.57
Monocytes（%） 0.5（0.0-2.0） 10.3（0.0-60.0） 0.15
Monocyte counts（× 103/μL） 0.014（0.00-0.056） 0.790（0.00-5.22） 0.15
Status of BM before GO infusion
Leukemic blasts（%） 47.7（4.2-89.0） 54.2（3.7-78.6） ＞ 0.99
Leukemic blast counts（×103/μL） 100.0（0.504-352.4） 84.1（2.22-151.5） 0.46
Monocytes（%） 0.65（0.0-2.2） 0.85（0.0-2.1） 0.57
Monocyte counts（× 103/μL） 0.100（0.00-0.264） 1.08（0.00-3.20） 0.048＊ 0.005＊
CD14 expression of leukemic blasts（%） 0.35（0.2-0.5） 2.6（1.2-5.1） 0.004＊ 0.66
CD33 expression of leukemic blasts（%） 58.4（17.2-95.0） 69.8（12.3-98.5） 0.46
No. of abnormalities of karyotypes 0.5（0-2） 9.5（0-30） 0.03＊ 0.002＊
Karyotypes grouped by SWOG cytogenetic risk category
　Favorable 0 0
0.01＊　Intermediate 3 1
　Unfavorable 0 7
　Unknown 1 0
Karyotypes grouped by MRC cytogenetic risk category
　Favorable 0 1
0.049＊　Intermediate 4 2
　Adverse 0 5
OR, overall response ; NR, no remission ; AML, acute myeloid leukemia ; FAB, French-American-British classica-
tion ; WBC, white blood cells ; NCC, nucleated cell counts ; GO, gemtuzumab ozogamicin ; PB, peripheral blood ; 
BM, bone marrow ; ECOG, Eastern Cooperative Oncology Group ; CR1, initial complete remission ; SWOG, 
Southwest Oncology Group ; MRC, Medical Research Council ; ＊, p＜ 0.05.
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Adverse events
　Elevation of transaminase and total bilirubin （grade 3） was observed in 1 case.  In 
another case, an infusion reaction was observed with a transient decrease in percutaneous 
oxygen saturation and fever （grade 3）.  The infusion reaction was resolved with glucocorti-
coid therapy.  BM suppression resulting in neutropenia （≤ 500/μL, grade 4） and thrombocy-
topenia （≤ 50,000/μL, grade 3） was observed in all patients.  Febrile neutropenia occurred 
in 11 patients （91.7%）, while grade 2 nausea and vomiting was observed in 1 patient.
　WBC counts and leukemic blasts in PB decreased in all patients after GO infusion.  The 
kinetics of WBC decline after 14 days following the initial GO infusion did not differ sig-
nicantly between OR and NR patients （data not shown）.
Discussion
　In this study we retrospectively evaluated the use of GO in 12 patients and analyzed the 
factors that affected the outcome of GO therapy.  The OR rate for GO monotherapy has 
been previously reported as 17%-33%2）, which corresponds with the rate observed in our 
study （33%）.  In this study, a signicant difference was observed between OR and NR 
Fig. 1.   Overall survival among all patients who 
received gemtuzumab ozogamicin （n＝ 12）.
Fig. 2.  Overall survival （OR vs. NR）.
Fig. 3.  Event-free survival among patients who attained OR （n＝ 4）.
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patients for factors including OS, ECOG performance status, duration of CR1, time between 
diagnosis of leukemia and initial GO infusion, number of karyotype abnormalities before 
GO infusion, cytogenetic risk as defined by the SWOG and MRC classification systems, 
CD14 expression rate of leukemic blasts in BM, and monocyte count in the BM.
　The duration of CR1 was signicantly longer in OR patients, which was similar to the 
results of a previous study 7）.  Additionally, the time from diagnosis of leukemia to GO 
infusion was signicantly longer in OR patients.  These ndings suggest that GO therapy is 
effective in patients who have been previously successfully treated with conventional chemo-
therapy.  Previous studies have reported that P-glycoprotein and multi-drug resistance protein 
expressions are associated with GO therapy outcomes 1, 4） and conventional chemotherapy 
outcomes 11）.  Thus, we consider sensitivity to conventional chemotherapy an important prog-
nostic factor for GO therapy.
　Similar to previous reports, no relationship was observed between the CD33 expression 
rate on leukemic blasts and the outcome of GO therapy 1, 5, 12）.  In our study, a patient 
（patient no. 3） with a CD33 expression rate of ＜ 20% achieved CR, while CR has also 
been reported in a CD33-negative patient 5）.  Furthermore, internalization of GO without 
intermediation by CD33 via endocytosis has been previously demonstrated 13）.  These results 
suggest that it is not possible to predict the effects of GO therapy based on CD33 expres-
sion rates alone, and that GO should not be excluded from the therapeutic options even for 
patients decient in CD33-positive leukemic cells.
　Interestingly, CD33 is known to be expressed on monocytes, and GO-induced apoptosis 
of monocytes has been previously reported 14, 15）.  Van der Velden et al demonstrated that 
a high CD33-antigen load in PB is an independent adverse prognostic factor, likely due to 
peripheral consumption of GO 6）.  In our study, the CD14 expression rate and monocyte 
count in the BM were signicantly lower in the OR group as compared to the NR group. 
Additionally, the monocyte count in the BM was signicantly associated with OS in a mul-
tivariate analysis.  However, there are no reports regarding an association between monocyte 
count or CD14 expression rate and GO therapy outcomes.  The reason why GO therapy 
failed in patients with high monocyte counts is not clear.  Further studies are needed to 
clarify the association between monocyte counts and GO therapy outcomes.
　In our study, both the number of karyotype abnormalities and the SWOG/MRC cyto-
genetic risk were signicantly different between NR and OR patients before GO infusion, 
which support a previous study reporting an association between MRC cytogenetic risk and 
clinical outcomes of GO therapy 7）.  These ndings suggest that the number of karyotype 
abnormalities and cytogenetic risk are predictive factors for GO therapy outcomes.
　In classical AML treatment, older patients are known to have poorer outcomes than 
younger patients 16）.  However, a previous study has demonstrated that GO is well-tolerated 
by elderly patients aged ≥ 60 years 16）; moreover, no signicant difference has been observed 
in the OR rate of GO therapy between patients aged＜ 60 and ≥ 60 years 7）.  For patients 
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aged＞ 75 years, Amadori et al concluded that a dose of 9 mg/m2 of GO was too toxic 17）. 
Since the OR patients in our study comprised only those aged ≥ 64 years （age range, 64-85 
years）, the tolerability of GO at a dosage of 9 mg/m2 could be veried for those aged at 
least ≤ 75 years.
　An adverse event of grade 3 or higher neutropenia was encountered in all patients.  This 
nding was similar to the 98% incidence of high-grade neutropenia reported by Larson et al 
in 2005 7）.  The presentation rate for febrile neutropenia in our study was 92%, which was 
higher than that in previous reports （6%7）, 31%18）, and 52%17））.  A grade 3 or higher infu-
sion reaction was noted in 1 patient （8%）; this incidence was lower than that described in 
previous reports （24%18）, and 30%7））.
　Previous analyses concluded that patients undergoing SCT within a short interval following 
GO administration are at an increased risk of developing VOD 19）.  In our study, no cases 
of VOD or sinusoidal obstruction syndrome were observed in the 6 patients who underwent 
allo-SCT following GO therapy.  The absence of VOD/sinusoidal obstruction syndrome in 
our study may be due to the small number of patients evaluated.
　Although our study was limited by the small number of patients included, we consider 
the following inferences important.  Our results suggest that patients showing good sensitiv-
ity to conventional chemotherapy with mild disease progression would benefit from GO 
therapy as well, and that GO is well tolerated even in elderly patients with relapsed leu-
kemia.  Our study also suggests that a low monocyte count in the BM at the time of GO 
infusion might indicate an improved efcacy of GO.  However, GO monotherapy is limited 
in its efcacy.  The combination of GO with other antileukemic agents is known to improve 
the response to GO therapy 2）.  Additionally, the administration of GO a few days after 
conventional chemotherapy appears to provide improved response and survival as compared 
to GO monotherapy 20）.  Further clinical trials with large sample groups are necessary to 
establish the efcacy of GO and to determine the group of patients most likely to benet 
from GO therapy.
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